-
1
-
-
3042845754
-
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
-
DOI 10.1172/JCI200422147
-
B.J. Nickoloff, and F.O. Nestle Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities J Clin Invest 113 2004 1664 1675 (Pubitemid 39071656)
-
(2004)
Journal of Clinical Investigation
, vol.113
, Issue.12
, pp. 1664-1675
-
-
Nickoloff, B.J.1
Nestle, F.O.2
-
2
-
-
33847129288
-
National Psoriasis Foundation clinical consensus on disease severity
-
DOI 10.1001/archderm.143.2.239
-
D.M. Pariser, J. Bagel, J.M. Gelfand, N.J. Korman, C.T. Ritchlin, and B.E. Strober National Psoriasis Foundation clinical consensus on disease severity Arch Dermatol 143 2007 239 242 (Pubitemid 46294591)
-
(2007)
Archives of Dermatology
, vol.143
, Issue.2
, pp. 239-242
-
-
Pariser, D.M.1
Bagel, J.2
Gelfand, J.M.3
Korman, N.J.4
Ritchlin, C.T.5
Strober, B.E.6
Van Voorhees, A.S.7
Young, M.8
Rittenberg, S.9
Lebwohl, M.G.10
Horn, E.J.11
-
3
-
-
6344289544
-
Etanercept for the treatment of psoriasis and psoriatic arthritis
-
DOI 10.1111/j.1396-0296.2004.04043.x
-
A.B. Gottlieb Etanercept for the treatment of psoriasis and psoriatic arthritis Dermatol Ther 17 2004 401 408 (Pubitemid 39390594)
-
(2004)
Dermatologic Therapy
, vol.17
, Issue.5
, pp. 401-408
-
-
Gottlieb, A.B.1
-
4
-
-
32244438261
-
Fulfilling an unmet need in psoriasis: Do biologicals hold the key to improved tolerability?
-
DOI 10.2165/00002018-200629010-00004
-
N.H. Shear Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 29 2006 49 66 (Pubitemid 43213895)
-
(2006)
Drug Safety
, vol.29
, Issue.1
, pp. 49-66
-
-
Shear, N.H.1
-
5
-
-
33748784859
-
The risk of lymphoma in patients with psoriasis
-
DOI 10.1038/sj.jid.5700410, PII 5700410
-
J.M. Gelfand, D.B. Shin, A.L. Neimann, X. Wang, D.J. Margolis, and A.B. Troxel The risk of lymphoma in patients with psoriasis J Invest Dermatol 126 2006 2194 2201 (Pubitemid 44413165)
-
(2006)
Journal of Investigative Dermatology
, vol.126
, Issue.10
, pp. 2194-2201
-
-
Gelfand, J.M.1
Shin, D.B.2
Neimann, A.L.3
Wang, X.4
Margolis, D.J.5
Troxel, A.B.6
-
6
-
-
0242660438
-
Lymphoma Rates Are Low but Increased in Patients with Psoriasis: Results from a Population-Based Cohort Study in the United Kingdom
-
DOI 10.1001/archderm.139.11.1425
-
J.M. Gelfand, J. Berlin, A. Van Voorhees, and D.J. Margolis Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom Arch Dermatol 139 2003 1425 1429 (Pubitemid 37433132)
-
(2003)
Archives of Dermatology
, vol.139
, Issue.11
, pp. 1425-1429
-
-
Gelfand, J.M.1
Berlin, J.2
Van Voorhees, A.3
Margolis, D.J.4
-
7
-
-
0034046385
-
Psoriasis, its treatment, and cancer in a cohort of finnish patients
-
DOI 10.1046/j.1523-1747.2000.00898.x
-
A. Hannuksela-Svahn, E. Pukkala, E. Laara, K. Poikolainen, and J. Karvonen Psoriasis, its treatment, and cancer in a cohort of Finnish patients J Invest Dermatol 114 2000 587 590 (Pubitemid 30415349)
-
(2000)
Journal of Investigative Dermatology
, vol.114
, Issue.3
, pp. 587-590
-
-
Hannuksela-Svahn, A.1
Pukkala, E.2
Laara, E.3
Poikolainen, K.4
Karvonen, J.5
-
8
-
-
0034973031
-
The risk of malignancy associated with psoriasis
-
D. Margolis, W. Bilker, S. Hennessy, C. Vittorio, J. Santanna, and B.L. Strom The risk of malignancy associated with psoriasis Arch Dermatol 137 2001 778 783 (Pubitemid 32577862)
-
(2001)
Archives of Dermatology
, vol.137
, Issue.6
, pp. 778-783
-
-
Margolis, D.1
Bilker, W.2
Hennessy, S.3
Vittorio, C.4
Santanna, J.5
Strom, B.L.6
-
9
-
-
0344926414
-
Etanercept as Monotherapy in Patients with Psoriasis
-
DOI 10.1056/NEJMoa030409
-
C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022 (Pubitemid 37448924)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.21
, pp. 2014-2022
-
-
Leonardi, C.L.1
Powers, J.L.2
Matheson, R.T.3
Goffe, B.S.4
Zitnik, R.5
Wang, A.6
Gottlieb, A.B.7
-
10
-
-
21644481166
-
A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction
-
DOI 10.1111/j.1365-2133.2005.06688.x
-
K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, and A.M. Nakanishi A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312 (Pubitemid 40933433)
-
(2005)
British Journal of Dermatology
, vol.152
, Issue.6
, pp. 1304-1312
-
-
Papp, K.A.1
Tyring, S.2
Lahfa, M.3
Prinz, J.4
Griffiths, C.E.M.5
Nakanishi, A.M.6
Zitnik, R.7
Van De Kerkhof, P.C.M.8
-
11
-
-
29844440963
-
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial
-
DOI 10.1016/S0140-6736(05)67763-X, PII S014067360567763X
-
S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, and A. Wang Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial Lancet 367 2006 29 35 (Pubitemid 43038667)
-
(2006)
Lancet
, vol.367
, Issue.9504
, pp. 29-35
-
-
Tyring, S.1
Gottlieb, A.2
Papp, K.3
Gordon, K.4
Leonardi, C.5
Wang, A.6
Lalla, D.7
Woolley, M.8
Jahreis, A.9
Zitnik, R.10
Cella, D.11
Krishnan, R.12
-
12
-
-
28844490562
-
Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial
-
DOI 10.1111/j.1365-2133.2005.06948.x
-
G.G. Krueger, R.G. Langley, A.Y. Finlay, C.E. Griffiths, J.M. Woolley, and D. Lalla Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial Br J Dermatol 153 2005 1192 1199 (Pubitemid 41779576)
-
(2005)
British Journal of Dermatology
, vol.153
, Issue.6
, pp. 1192-1199
-
-
Krueger, G.G.1
Langley, R.G.2
Finlay, A.Y.3
Griffiths, C.E.M.4
Woolley, J.M.5
Lalla, D.6
Jahreis, A.7
-
13
-
-
27144456788
-
Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial
-
DOI 10.1016/j.jaad.2005.06.053, PII S0190962205023017
-
S.R. Feldman, A.B. Kimball, G.G. Krueger, J.M. Woolley, D. Lalla, and A. Jahreis Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial J Am Acad Dermatol 53 2005 887 889 (Pubitemid 41501389)
-
(2005)
Journal of the American Academy of Dermatology
, vol.53
, Issue.5
, pp. 887-889
-
-
Feldman, S.R.1
Kimball, A.B.2
Krueger, G.G.3
Woolley, J.M.4
Lalla, D.5
Jahreis, A.6
-
14
-
-
32644479353
-
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy
-
DOI 10.1080/09546630500472838, PII K84147557M477J51
-
K.B. Gordon, A.B. Gottlieb, C.L. Leonardi, B.E. Elewski, A. Wang, and A. Jahreis Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy J Dermatolog Treat 17 2006 9 17 (Pubitemid 43247302)
-
(2006)
Journal of Dermatological Treatment
, vol.17
, Issue.1
, pp. 9-17
-
-
Gordon, K.B.1
Gottlieb, A.B.2
Leonardi, C.L.3
Elewski, B.E.4
Wang, A.5
Jahreis, A.6
Zitnik, R.7
-
15
-
-
10744221697
-
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
-
DOI 10.1001/archderm.139.12.1627
-
A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, and B.S. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632 (Pubitemid 37523083)
-
(2003)
Archives of Dermatology
, vol.139
, Issue.12
, pp. 1627-1632
-
-
Gottlieb, A.B.1
Matheson, R.T.2
Lowe, N.3
Krueger, G.G.4
Kang, S.5
Goffe, B.S.6
Gaspari, A.A.7
Ling, M.8
Weinstein, G.D.9
Nayak, A.10
Gordon, K.B.11
Zitnik, R.12
Naldi, L.13
-
16
-
-
44049097512
-
Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: Continuous versus interrupted treatment
-
DOI 10.1111/j.1524-4733.2007.00251.x
-
J.M. Gelfand, A.B. Kimball, E.N. Mostow, C.F. Chiou, V. Patel, and H.A. Xia Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment Value Health 11 2008 400 407 (Pubitemid 351712967)
-
(2008)
Value in Health
, vol.11
, Issue.3
, pp. 400-407
-
-
Gelfand, J.M.1
Kimball, A.B.2
Mostow, E.N.3
Chiou, C.-F.4
Patel, V.5
Xia, H.A.6
Freundlich, B.7
Stevens, S.R.8
-
17
-
-
54249097066
-
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension
-
P.C. van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, and A. Kaszuba Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension Br J Dermatol 159 2008 1177 1185
-
(2008)
Br J Dermatol
, vol.159
, pp. 1177-1185
-
-
Van De Kerkhof, P.C.1
Segaert, S.2
Lahfa, M.3
Luger, T.A.4
Karolyi, Z.5
Kaszuba, A.6
-
18
-
-
32644448881
-
Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial
-
G.G. Krueger, B. Elewski, K. Papp, A. Wang, R. Zitnik, and A. Jahreis Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial J Am Acad Dermatol 54 Suppl 2006 S112 S119
-
(2006)
J Am Acad Dermatol
, vol.54
, Issue.SUPPL.
-
-
Krueger, G.G.1
Elewski, B.2
Papp, K.3
Wang, A.4
Zitnik, R.5
Jahreis, A.6
-
19
-
-
33144490233
-
Long term safety of etanercept in elderly subjects with rheumatic diseases
-
DOI 10.1136/ard.2005.035287
-
R. Fleischmann, S.W. Baumgartner, M.H. Weisman, T. Liu, B. White, and P. Peloso Long-term safety of etanercept in elderly subjects with rheumatic diseases Ann Rheum Dis 65 2006 379 384 (Pubitemid 43268229)
-
(2006)
Annals of the Rheumatic Diseases
, vol.65
, Issue.3
, pp. 379-384
-
-
Fleischmann, R.1
Baumgartner, S.W.2
Weisman, M.H.3
Liu, T.4
White, B.5
Peloso, P.6
-
20
-
-
33646464514
-
Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience
-
L.W. Moreland, M.E. Weinblatt, E.C. Keystone, J.M. Kremer, R.W. Martin, and M.H. Schiff Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience J Rheumatol 33 2006 854 861
-
(2006)
J Rheumatol
, vol.33
, pp. 854-861
-
-
Moreland, L.W.1
Weinblatt, M.E.2
Keystone, E.C.3
Kremer, J.M.4
Martin, R.W.5
Schiff, M.H.6
-
21
-
-
33751268255
-
A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
-
DOI 10.1136/ard.2005.038349
-
L. Klareskog, M. Gaubitz, V. Rodriguez-Valverde, M. Malaise, M. Dougados, and J. Wajdula A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs Ann Rheum Dis 65 2006 1578 1584 (Pubitemid 44799668)
-
(2006)
Annals of the Rheumatic Diseases
, vol.65
, Issue.12
, pp. 1578-1584
-
-
Klareskog, L.1
Gaubitz, M.2
Rodriguez-Valverde, V.3
Malaise, M.4
Dougados, M.5
Wajdula, J.6
-
22
-
-
67549117204
-
The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events
-
J.P. Leombruno, T.R. Einarson, and E.C. Keystone The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Ann Rheum Dis 68 2009 1136 1145
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1136-1145
-
-
Leombruno, J.P.1
Einarson, T.R.2
Keystone, E.C.3
-
23
-
-
79952610089
-
-
Enbrel [etanercept] Immunex Corp, marketed by Amgen and Wyeth Pharmaceuticals Thousand Oaks (CA)
-
Enbrel [etanercept] Full Prescribing Information 2010 Immunex Corp, marketed by Amgen and Wyeth Pharmaceuticals Thousand Oaks (CA)
-
(2010)
Full Prescribing Information
-
-
-
24
-
-
34250761386
-
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
-
DOI 10.1001/archderm.143.6.719
-
S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726 (Pubitemid 46955730)
-
(2007)
Archives of Dermatology
, vol.143
, Issue.6
, pp. 719-726
-
-
Tyring, S.1
Gordon, K.B.2
Poulin, Y.3
Langley, R.G.4
Gottlieb, A.B.5
Dunn, M.6
Jahreis, A.7
-
25
-
-
33947182547
-
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis
-
DOI 10.1016/j.jaad.2006.09.002, PII S0190962206025266
-
A. Moore, K.B. Gordon, S. Kang, A. Gottlieb, B. Freundlich, and H.A. Xia A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis J Am Acad Dermatol 56 2007 598 603 (Pubitemid 46400183)
-
(2007)
Journal of the American Academy of Dermatology
, vol.56
, Issue.4
, pp. 598-603
-
-
Moore, A.1
Gordon, K.B.2
Kang, S.3
Gottlieb, A.4
Freundlich, B.5
Xia, H.A.6
Stevens, S.R.7
-
26
-
-
77955868573
-
Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study
-
C. Leonardi, B. Strober, A.B. Gottlieb, B.E. Elewski, J.P. Ortonne, and P. van de Kerkhof Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study J Drugs Dermatol 9 2010 928 937
-
(2010)
J Drugs Dermatol
, vol.9
, pp. 928-937
-
-
Leonardi, C.1
Strober, B.2
Gottlieb, A.B.3
Elewski, B.E.4
Ortonne, J.P.5
Van De Kerkhof, P.6
-
27
-
-
84873612401
-
-
Amgen Inc [ identifier NCT00121615 ] Available from Accessed April 25 2011
-
Amgen Inc. Study of etanercept in the treatment of psoriasis in adult subjects [ ClinicalTrials.gov identifier NCT00121615 ]. Available from: http://clinicaltrials.gov/ct2/show/NCT00121615?term= etanercept+and+psoriasis&rank=39. Accessed April 25, 2011.
-
Study of Etanercept in the Treatment of Psoriasis in Adult Subjects
-
-
-
28
-
-
84873609770
-
-
National Cancer Institute Available from:. Accessed April 12 2011
-
National Cancer Institute. Common toxicity criteria, version 2.0. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcv20-4-30-992.pdf. Accessed April 12, 2011.
-
Common Toxicity Criteria, Version 2.0.
-
-
-
29
-
-
0348243012
-
-
Maintenance and support services organization. Available from:. Accessed April 25 2011
-
Medical Dictionary for Regulatory Activities (MedDRA) Version 7.0. Maintenance and support services organization. Available from: http://www.meddramsso.com/. Accessed April 25, 2011.
-
Medical Dictionary for Regulatory Activities (MedDRA) Version 7.0
-
-
-
31
-
-
84873610078
-
-
National Cancer Institute November 2005 submission (1992-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission. Available from:. Accessed April 25 2011
-
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program SEERStat database: incidence-SEER 13 Regs public-use, November 2005 submission (1992-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission. Available from: http://www.seer.cancer.gov/. Accessed April 25, 2011.
-
Surveillance, Epidemiology, and End Results (SEER) Program SEERStat Database: Incidence-SEER 13 Regs Public-use
-
-
-
32
-
-
0030912824
-
Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992
-
D.T. Gray, V.J. Suman, W.P. Su, R.P. Clay, W.S. Harmsen, and R.K. Roenigk Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992 Arch Dermatol 133 1997 735 740 (Pubitemid 27263707)
-
(1997)
Archives of Dermatology
, vol.133
, Issue.6
, pp. 735-740
-
-
Gray, D.T.1
Suman, V.J.2
Daniel Su, W.P.3
Clay, R.P.4
Harmsen, W.S.5
Roenigk, R.K.6
-
33
-
-
0034816721
-
Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996
-
DOI 10.1067/mjd.2001.114742
-
R.B. Harris, K. Griffith, and T.E. Moon Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996 J Am Acad Dermatol 45 2001 528 536 (Pubitemid 32917246)
-
(2001)
Journal of the American Academy of Dermatology
, vol.45
, Issue.4
, pp. 528-536
-
-
Harris, R.B.1
Griffith, K.2
Moon, T.E.3
-
34
-
-
32644437923
-
Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database
-
A.B. Gottlieb, C.L. Leonardi, B.S. Goffe, J.-P. Ortonne, P. van der Kerkhof, and R. Zitnick Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database J Am Acad Dermatol 54 Suppl 2006 S92 S100
-
(2006)
J Am Acad Dermatol
, vol.54
, Issue.SUPPL.
-
-
Gottlieb, A.B.1
Leonardi, C.L.2
Goffe, B.S.3
Ortonne, J.-P.4
Van Der Kerkhof, P.5
Zitnick, R.6
-
35
-
-
80052991902
-
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications
-
A.B. Gottlieb, K. Gordon, E.H. Giannini, P. Mease, J. Li, and Y. Chon Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications J Drugs Dermatol 10 2011 289 300
-
(2011)
J Drugs Dermatol
, vol.10
, pp. 289-300
-
-
Gottlieb, A.B.1
Gordon, K.2
Giannini, E.H.3
Mease, P.4
Li, J.5
Chon, Y.6
-
37
-
-
24944529247
-
TNF-blocking agents and tuberculosis: New drugs illuminate an old topic
-
DOI 10.1093/rheumatology/keh567
-
J. Keane TNF-blocking agents and tuberculosis: new drugs illuminate an old topic Rheumatology (Oxford) 44 2005 714 720 (Pubitemid 41487198)
-
(2005)
Rheumatology
, vol.44
, Issue.6
, pp. 714-720
-
-
Keane, J.1
-
38
-
-
33749613119
-
Risk of myocardial infarction in patients with psoriasis
-
DOI 10.1001/jama.296.14.1735
-
J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741 (Pubitemid 44547793)
-
(2006)
Journal of the American Medical Association
, vol.296
, Issue.14
, pp. 1735-1741
-
-
Gelfand, J.M.1
Neimann, A.L.2
Shin, D.B.3
Wang, X.4
Margolis, D.J.5
Troxel, A.B.6
-
39
-
-
33947139769
-
The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case-control study
-
DOI 10.1016/j.jaad.2006.09.017, PII S0190962206025436
-
J. Shapiro, A.D. Cohen, M. David, E. Hodak, G. Chodik, and A. Viner The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study J Am Acad Dermatol 56 2007 629 634 (Pubitemid 46400186)
-
(2007)
Journal of the American Academy of Dermatology
, vol.56
, Issue.4
, pp. 629-634
-
-
Shapiro, J.1
Cohen, A.D.2
David, M.3
Hodak, E.4
Chodik, G.5
Viner, A.6
Kremer, E.7
Heymann, A.8
-
40
-
-
0035678652
-
Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden
-
DOI 10.1046/j.0022-202x.2001.01520.x
-
P. Boffetta, G. Gridley, and B. Lindelof Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden J Invest Dermatol 117 2001 1531 1537 (Pubitemid 34032784)
-
(2001)
Journal of Investigative Dermatology
, vol.117
, Issue.6
, pp. 1531-1537
-
-
Boffetta, P.1
Gridley, G.2
Lindelof, B.3
-
41
-
-
0032838965
-
PUVA and cancer risk: The Swedish follow-up study
-
DOI 10.1046/j.1365-2133.1999.02928.x
-
B. Lindelof, B. Sigurgeirsson, E. Tegner, O. Larko, A. Johannesson, and B. Berne PUVA and cancer risk: the Swedish follow-up study Br J Dermatol 141 1999 108 112 (Pubitemid 29333701)
-
(1999)
British Journal of Dermatology
, vol.141
, Issue.1
, pp. 108-112
-
-
Lindelof, B.1
Sigurgeirsson, B.2
Tegner, E.3
Larko, O.4
Johannesson, A.5
Berne, B.6
Ljunggren, B.7
Andersson, T.8
Molin, L.9
Nylander-Lundqvist, E.10
Emtestam, L.11
-
42
-
-
15044361996
-
High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients
-
DOI 10.1111/j.0022-202X.2005.23618.x
-
J.L. Lim, and R.S. Stern High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients J Invest Dermatol 124 2005 505 513 (Pubitemid 40381572)
-
(2005)
Journal of Investigative Dermatology
, vol.124
, Issue.3
, pp. 505-513
-
-
Lim, J.L.1
Stern, R.S.2
-
43
-
-
19444375889
-
Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use
-
S.M. Behnam, S.E. Behnam, and J.Y. Koo Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use J Drugs Dermatol 4 2005 189 194
-
(2005)
J Drugs Dermatol
, vol.4
, pp. 189-194
-
-
Behnam, S.M.1
Behnam, S.E.2
Koo, J.Y.3
-
44
-
-
45349083403
-
Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate
-
DOI 10.1002/art.23716
-
R. Buchbinder, M. Barber, L. Heuzenroeder, A.E. Wluka, G. Giles, and S. Hall Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate Arthritis Rheum 59 2008 794 799 (Pubitemid 351847561)
-
(2008)
Arthritis Care and Research
, vol.59
, Issue.6
, pp. 794-799
-
-
Buchbinder, R.1
Barber, M.2
Heuzenroeder, L.3
Wluka, A.E.4
Giles, G.5
Hall, S.6
Harkness, A.7
Lewis, D.8
Littlejohn, G.9
Miller, M.H.10
Ryan, P.F.J.11
Jolley, D.12
-
45
-
-
77949405816
-
Incidence estimate of nonmelanoma skin cancer in the United States, 2006
-
H.W. Rogers, M.A. Weinstock, A.R. Harris, M.R. Hinckley, S.R. Feldman, and A.B. Fleischer Incidence estimate of nonmelanoma skin cancer in the United States, 2006 Arch Dermatol 146 2010 283 287
-
(2010)
Arch Dermatol
, vol.146
, pp. 283-287
-
-
Rogers, H.W.1
Weinstock, M.A.2
Harris, A.R.3
Hinckley, M.R.4
Feldman, S.R.5
Fleischer, A.B.6
-
46
-
-
34848893989
-
Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study
-
DOI 10.1002/art.22864
-
F. Wolfe, and K. Michaud Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study Arthritis Rheum 56 2007 2886 2895 (Pubitemid 47502734)
-
(2007)
Arthritis and Rheumatism
, vol.56
, Issue.9
, pp. 2886-2895
-
-
Wolfe, F.1
Michaud, K.2
-
47
-
-
0035674613
-
Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides
-
DOI 10.1002/1529-0131(200 112)44:12<2862::A ID-ART474>3.0.CO;2-W
-
N. Mohan, E.T. Edwards, T.R. Cupps, P.J. Oliverio, G. Sandberg, and H. Crayton Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides Arthritis Rheum 44 2001 2862 2869 (Pubitemid 34016206)
-
(2001)
Arthritis and Rheumatism
, vol.44
, Issue.12
, pp. 2862-2869
-
-
Mohan, N.1
Edwards, E.T.2
Cupps, T.R.3
Oliverio, P.J.4
Sandberg, G.5
Crayton, H.6
Richert, J.R.7
Siegel, J.N.8
-
48
-
-
33644875213
-
TNF-alpha inhibitors and congestive heart failure
-
S.M. Behnam, S.E. Behnam, and J.Y. Koo TNF-alpha inhibitors and congestive heart failure Skinmed 4 2005 363 368
-
(2005)
Skinmed
, vol.4
, pp. 363-368
-
-
Behnam, S.M.1
Behnam, S.E.2
Koo, J.Y.3
|